Analysts’ Weekly Ratings Updates for Esperion Therapeutics (ESPR)

Several analysts have recently updated their ratings and price targets for Esperion Therapeutics (NASDAQ: ESPR):

• 5/4/2026 – Esperion Therapeutics was downgraded by Needham & Company LLC from “buy” to “hold”.
• 5/1/2026 – Esperion Therapeutics was downgraded by Jefferies Financial Group Inc. from “strong-buy” to “hold”.
• 5/1/2026 – Esperion Therapeutics was downgraded by Citizens Jmp from “strong-buy” to “hold”.
• 5/1/2026 – Esperion Therapeutics was downgraded by Piper Sandler from “strong-buy” to “hold”.
• 5/1/2026 – Esperion Therapeutics was downgraded by Cantor Fitzgerald from “strong-buy” to “hold”.
• 5/1/2026 – Esperion Therapeutics was downgraded by HC Wainwright from “buy” to “neutral”. They now have a $3.16 price target on the stock.
• 4/21/2026 – Esperion Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 3/14/2026 – Esperion Therapeutics was upgraded by Wall Street Zen from “hold” to “buy”.
• 3/13/2026 – Esperion Therapeutics had its price target raised by Citizens Jmp from $4.00 to $5.00. They now have a “market outperform” rating on the stock.

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.